Remedium Bio, a portfolio company of LifeSpan Vision Ventures, has entered into a multi-target research and development collaboration with Eli Lilly to advance gene therapies targeting type 2 diabetes and obesity, according to the company.
Under the deal, Remedium will leverage its proprietary Prometheus™ platform—designed to enable long-acting, adjustable-dose gene therapies—to jointly develop potential one-time treatments administered via subcutaneous injection. The company claims the approach could replace recurring protein-based injections with more consistent and cost-effective therapies.
The agreement provides Remedium with an upfront payment, an equity investment and potential milestone payments tied to development and commercialization. Remedium is also eligible to receive tiered royalties on worldwide net sales of any resulting products.
The partnership aims to pair Remedium’s gene therapy platform with Lilly’s expertise in metabolic disease therapeutics. Remedium asserts its technology offers durable, tunable control over therapeutic protein expression, which could reshape treatment of cardiometabolic conditions.
The collaboration adds to Remedium’s existing pipeline, which the company says spans endocrinology, immunology, neurology and musculoskeletal disease areas.
